The protective role of molsidomine on the Cisplatin-induced ototoxicity
This experimental study was designed to investigate the protective effects of molsidomine (MOL) on against cisplatin-induced ototoxicity (CIO). To examine this effect, distortion product otoacoustic emissions (DPOAEs) measurements and serum levels of oxidative and antioxidant status [including malondialdehyde (MDA), superoxide dismutase (SOD), catalase (CAT), glutathione (GSH), glutathione peroxidase (GPX), total oxidant status (TOS), total antioxidant status (TAS), and oxidative stress index (OSI)] were evaluated. Thirty-two female wistar albino rats were divided into four groups including; control (Group K), cisplatin (Group C), cisplatin plus MOL group (Group CM), and MOL group (Group M). DPOAEs measurements between 0.9961 and 8.0003 Hz as DP-gram and input/output (I/O) functions were performed in the same (left) ear of all rats on days 0, 1st, 5th and 12th. Prior to death, the last DPOAEs measurements and blood samples were taken. In the C group, statistically significant DPOAE amplitude reductions were detected at 2.5195, 3.1758, 3.9961, 5.0391, 6.3516 and 8.0039 Hz frequencies (p < 0.05) between 0th and 1st, 0th and 5th and 0th and 12th days' measurements (p < 0.05). Serum level of MDA, TAC and OSI levels were significantly higher in the C group versus K group (p < 0.05). In the CM group, there were no significant differences at all frequencies between 0th and other days' measurements (p > 0.05) and the serum levels of all biochemical parameters were shifted toward normal values, similar to the K group (p < 0.05). No significant differences were detected in the either M or K group's measurements. According to these results, cisplatin-related ototoxicity has been significantly prevented by MOL.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:66 |
|---|---|
| Enthalten in: |
Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India - 66(2014), 3 vom: 24. Sept., Seite 314-9 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Toplu, Yuksel [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cisplatin |
|---|
| Anmerkungen: |
Date Completed 17.07.2014 Date Revised 21.10.2021 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1007/s12070-014-0718-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM240140753 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM240140753 | ||
| 003 | DE-627 | ||
| 005 | 20231224121454.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12070-014-0718-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0800.xml |
| 035 | |a (DE-627)NLM240140753 | ||
| 035 | |a (NLM)25032121 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Toplu, Yuksel |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The protective role of molsidomine on the Cisplatin-induced ototoxicity |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.07.2014 | ||
| 500 | |a Date Revised 21.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a This experimental study was designed to investigate the protective effects of molsidomine (MOL) on against cisplatin-induced ototoxicity (CIO). To examine this effect, distortion product otoacoustic emissions (DPOAEs) measurements and serum levels of oxidative and antioxidant status [including malondialdehyde (MDA), superoxide dismutase (SOD), catalase (CAT), glutathione (GSH), glutathione peroxidase (GPX), total oxidant status (TOS), total antioxidant status (TAS), and oxidative stress index (OSI)] were evaluated. Thirty-two female wistar albino rats were divided into four groups including; control (Group K), cisplatin (Group C), cisplatin plus MOL group (Group CM), and MOL group (Group M). DPOAEs measurements between 0.9961 and 8.0003 Hz as DP-gram and input/output (I/O) functions were performed in the same (left) ear of all rats on days 0, 1st, 5th and 12th. Prior to death, the last DPOAEs measurements and blood samples were taken. In the C group, statistically significant DPOAE amplitude reductions were detected at 2.5195, 3.1758, 3.9961, 5.0391, 6.3516 and 8.0039 Hz frequencies (p < 0.05) between 0th and 1st, 0th and 5th and 0th and 12th days' measurements (p < 0.05). Serum level of MDA, TAC and OSI levels were significantly higher in the C group versus K group (p < 0.05). In the CM group, there were no significant differences at all frequencies between 0th and other days' measurements (p > 0.05) and the serum levels of all biochemical parameters were shifted toward normal values, similar to the K group (p < 0.05). No significant differences were detected in the either M or K group's measurements. According to these results, cisplatin-related ototoxicity has been significantly prevented by MOL | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cisplatin | |
| 650 | 4 | |a Molsidomine | |
| 650 | 4 | |a Otoacoustic emissions | |
| 650 | 4 | |a Ototoxicity | |
| 650 | 4 | |a Oxidative status | |
| 700 | 1 | |a Parlakpinar, Hakan |e verfasserin |4 aut | |
| 700 | 1 | |a Sapmaz, Emrah |e verfasserin |4 aut | |
| 700 | 1 | |a Karatas, Erkan |e verfasserin |4 aut | |
| 700 | 1 | |a Polat, Alaattin |e verfasserin |4 aut | |
| 700 | 1 | |a Kizilay, Ahmet |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India |d 1997 |g 66(2014), 3 vom: 24. Sept., Seite 314-9 |w (DE-627)NLM093661746 |x 2231-3796 |7 nnns |
| 773 | 1 | 8 | |g volume:66 |g year:2014 |g number:3 |g day:24 |g month:09 |g pages:314-9 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12070-014-0718-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 66 |j 2014 |e 3 |b 24 |c 09 |h 314-9 | ||